Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

We reviewed preclinical data and clinical development of MDM2 (murine double minute 2), ALK (anaplastic lymphoma kinase) and PARP (poly [ADP-ribose] polymerase) inhibitors. MDM2 binds to p53, and promotes degradation of p53 through ubiquitin-proteasome degradation. JNJ-26854165 and RO5045337 are 2 s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yuan, Liao, Yu-Min, Hsueh, Chung-Tsen, Mirshahidi, Hamid R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103487/
https://www.ncbi.nlm.nih.gov/pubmed/21504625
http://dx.doi.org/10.1186/1756-8722-4-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103487/
https://www.ncbi.nlm.nih.gov/pubmed/21504625
http://dx.doi.org/10.1186/1756-8722-4-16

Ejemplares similares